| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash used in operating activities | -33,296,042 | -19,931,667 |
| Proceeds from the sale of assets, net of sales costs | 180,763 | 89,363 |
| Purchase of short-term investments, net of maturities | 16,871,229 | 24,747,039 |
| Purchase of property and equipment | 6,312 | 6,312 |
| Net cash used in investing activities | -16,696,778 | -24,663,988 |
| Purchase under employee stock purchase plan | 18,158 | 18,158 |
| Proceeds from the issuance of common stock and warrants, net of equity issuance costs of 0 and 6,434,447, respectively | 0 | 0 |
| Net cash provided by financing activities | 18,158 | 18,158 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -49,974,662 | -44,577,497 |
| Cash and cash equivalents at beginning of period | 68,415,741 | - |
| Cash and cash equivalents at end of period | 18,441,079 | - |
Skye Bioscience, Inc. (SKYE)
Skye Bioscience, Inc. (SKYE)